US price erosion: Pressure on Glenmark's business to continue

Company expects 10-12 per cent price erosion to continue in America

Glenmark is exploring if it should spin off its consumer health and Active Pharmaceutical Ingredients (API) businesses, the drug maker indicated after its March quarter results. The consumer health business, with sales of Rs 1.5 billion in FY18, is about six per cent of domestic sales and growing at a robust rate.

“Glenmark has appointed a committee to assess the feasibility of housing the API and consumer care businesses into separate subsidiaries. The rationale for evaluating this is to give better focus to these businesses, which we believe have good growth potential, and for a better structure and financial efficiencies for